MSB 10.4% $1.49 mesoblast limited

Overwhelming efficacy COVID19 ARDS - EUA dependent (denied if...

  1. 3,892 Posts.
    lightbulb Created with Sketch. 1320
    Overwhelming efficacy COVID19 ARDS - EUA dependent (denied if insufficient supply) on 3 way conversation Novartis - Mesoblast - Lonza, also congnisant of fact that requirements will very shortly, post EUA, be not just be inside USA, e.g. EU and many other places. Supply will be urgent given current people in need have at most days to weeks left.
    Last edited by Treed: 16/12/20
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Last
$1.49
Change
0.140(10.4%)
Mkt cap ! $1.701B
Open High Low Value Volume
$1.37 $1.54 $1.37 $23.10M 15.82M

Buyers (Bids)

No. Vol. Price($)
3 24758 $1.49
 

Sellers (Offers)

Price($) Vol. No.
$1.49 73626 3
View Market Depth
Last trade - 16.10pm 04/10/2024 (20 minute delay) ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.